Safety and Efficacy of an Adult Acute Lymphoblastic Leukemia Chemotherapy for Adult Lymphoblastic Lymphoma
A Multicenter, Phase 2 Study, to Evaluate Safety and Efficacy of an Acute Lymphoblastic Leukemia (ALL) Intensive Chemotherapy for Adult Lymphoblastic Lymphoma (LL).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Liege, Belgium, 4000
- CHR de la Citadelle
-
Yvoir, Belgium, 5530
- Cliniques Universitaires U C L de Mont Godinne
-
-
-
-
-
Angers, France, 49033
- C H U D'Angers
-
Annecy, France, 74011
- Centre Hospitalier de la région annécienne
-
Grenoble, France, 38043
- CHU de GRENOBLE
-
Lens, France, 62300
- Centre Hospitalier de Lens
-
Lyon, France, 69437
- Edouard Herriot Hospital
-
Lyon, France, 69495
- Pierre Benite Hospital
-
Marseilles, France, 13273
- Institut Paoli Calmettes
-
Paris, France, 75000
- Saint-Louis Hospital
-
Paris, France, 75013
- La Pitié Salpêtrière Hospital
-
Paris, France, 75014
- Cochin Hospital
-
Perpignan, France, 66046
- Marechal Joffre Hospital
-
Poitiers, France, 86000
- Centre Hospitalier de Poitiers
-
Reims, France, 51092
- Chu de Reims Robert Debre Hospital
-
Rouen, France, 76038
- Centre Henri Becquerel
-
Saint Priest En Jarez, France, 42271
- Institut de Cancérologie de la Loire
-
Tours, France, 37044
- Bretonneau Hospital
-
Vandoeuvre Les Nancy, France, 54511
- CHU de Brabois
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient with lymphoblastic lymphoma.
- Aged from 18 to 59 years.
- Medullary blasts rate less than 20%
- Non previously treated
- With or without central nervous system or meningeal involvement.
- No contra-indication to anthracyclines.
- No contra-indication to intensive treatments
- Negative HIV serology test
- Negative pregnancy test for all female patients of childbearing potential.
- Able to be regularly followed up.
Exclusion Criteria:
- Evolutive cancer with the exception of non melanoma skin tumours or stage 0 (in situ) cervical carcinoma.
- Prior treatment with chemotherapy.
- Lymphoblastic Transformation of chronic myeloid leukaemia
- Patient unable to be regularly followed-up.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Event free survival
Time Frame: 2 y
|
2 y
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Disease Free Survival ; Complete response rate ; Overall Survival ; Progression rate; Relapse rate ; Central Nervous System or meningeal relapse rate ; medullary relapse rate ; toxicities.
Time Frame: 2 y
|
2 y
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Stephane Lepretre, MD, Centre Henri Becquerel, Rouen, France
- Principal Investigator: Hervé Dombret, MD, Saint-Louis Hospital, Paris, France
- Principal Investigator: Norbert Ifrah, MD, Centre Hospitalier Universitaire d'Angers, FRANCE
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Leukemia
- Lymphoma
- Lymphoma, Non-Hodgkin
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Dermatologic Agents
- Antibiotics, Antineoplastic
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Cyclophosphamide
- Etoposide
- Prednisone
- Cytarabine
- Methotrexate
- Vincristine
- Daunorubicin
- Asparaginase
Other Study ID Numbers
Other Study ID Numbers
- LL03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.